RT Journal Article
T1 Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
A1 Corma-Gomez, Anaïs
A1 Fernandez-Fuertes, Marta
A1 Garcia, Estefania
A1 Fuentes-Lopez, Ana
A1 Gomez-Ayerbe, Cristina
A1 Rivero-Juarez, Antonio
A1 Dominguez, Carmen
A1 Santos, Marta
A1 Viñuela, Laura
A1 Palacios, Rosario
A1 Real, Luis M
A1 Rivero, Antonio
A1 Macias, Juan
A1 Pineda, Juan A
A1 Garcia, Federico
K1 CD4 T-cell counts
K1 Humoral response
K1 People living with HIV
K1 SARS-CoV-2
K1 Vaccine
K1 Área de Gestión Sanitaria Sur de Sevilla
AB The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts  HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts
PB Elsevier
YR 2022
FD 2022-05-14
LK http://hdl.handle.net/10668/22132
UL http://hdl.handle.net/10668/22132
LA en
NO Corma-Gómez A, Fernández-Fuertes M, García E, Fuentes-López A, Gómez-Ayerbe C, Rivero-Juárez A, et al. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clin Microbiol Infect. 2022 Nov;28(11):1492-1498
DS RISalud
RD Apr 5, 2025